FFO
ACTU

Fortitude Family Office’s Actuate Therapeutics ACTU Stock Holding History

Fortitude Family Office’s Portfolio ACTU Stock Details ACTU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$46 Buy
+30
New +$70 ﹤0.01% 2215

Other funds holding ACTU

GG
Gleason Group Prospect, Kentucky $1.15B AUM 21.11% 1-Year Est. Return
AWM
Apollon Wealth Management Mount Pleasant, South Carolina $8.23B AUM 30.88% 1-Year Est. Return
AA
ACT Advisors Asheville, North Carolina $301M AUM 23.36% 1-Year Est. Return
SFS
Sowell Financial Services North Little Rock, Arkansas $3.06B AUM 30.02% 1-Year Est. Return
GRWP
Green Ridge Wealth Planning Montville, New Jersey $238M AUM
EWA
EverSource Wealth Advisors Birmingham, Alabama $2.97B AUM 28.74% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return
TWD
True Wealth Design Akron, Ohio $420M AUM 22.7% 1-Year Est. Return

Fortitude Family Office's ACTU Position: Q2 2026 in Review

Fortitude Family Office opened a new position in Actuate Therapeutics (ACTU) in Q2 2026: 30 shares worth $46. The stake represents ﹤0.01% of the portfolio and ranks #2215 among its holdings.

12 funds tracked by Wall St. Rank hold ACTU as of Q2 2026.

  • Fortitude Family Office held 30 shares of Actuate Therapeutics worth $46 as of Q2 2026.
  • Actuate Therapeutics was a new Fortitude Family Office position in Q2 2026.
  • Actuate Therapeutics made up ﹤0.01% of Fortitude Family Office's portfolio in Q2 2026, its #2215 holding.
  • 12 funds tracked by Wall St. Rank held Actuate Therapeutics as of Q2 2026.

Based on Fortitude Family Office's 13F filing for Q2 2026, filed 20 Jul 2026.